Navigation Links
Venaxis to Present at Three Upcoming Investor Conferences

CASTLE ROCK, Colo., Sept. 5, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will present at the Rodman & Renshaw Annual Global Investment Conference, to be held September 8 – 10, 2013, at the Millennium Broadway Hotel in New York, the Craig-Hallum 4th Annual Alpha Select Conference, to be held September 26, 2013, at the Convene 730 3rd Avenue in New York; as well as the Aegis Capital Vegas Healthcare Conference, to be held September 26 – 28, 2013, at the Wynn Las Vegas Hotel.Event:Rodman & Renshaw Annual Global Investment ConferenceDate: Monday, September 9, 2013 Time: 3:40 pm (Eastern Time) Location:Millennium Broadway Hotel; New York, NY 

Event:Craig-Hallum 4th Annual Alpha Select ConferenceDate: Thursday, September 26, 2013 Time: 3:10 pm (Eastern Time)Location:Flatiron Room; Convene 730 3rd Avenue; New York, NY 

Event:Aegis Capital Vegas Healthcare ConferenceDate: Thursday, September 26, 2013 Time: 11:30 am (Mountain Time) Location:Wynn Las Vegas Hotel; Las Vegas, NVSteve Lundy, President and CEO of Venaxis, will provide an overview of the Company's business at the Rodman & Renshaw and Craig-Hallum Conferences, and Don Hurd, Senior Vice President and Chief Commercial Officer of Venaxis, will present at the Aegis Capital Conference. Mr. Lundy and Mr. Hurd will be available to participate in one-on-one meetings with investors who are registered to attend the respective conferences. 

The Rodman & Renshaw presentation will be webcast. To access the webcast, please visit the investor relations section of the Venaxis website at The webcast replay will remain available for 90 days following each live presentation.

About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company's rapid, protein biomarker-based assay for appendicitis. This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management. The APPY1 Test is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging. While FDA clearance is being sought, an initial launch for the APPY1 Test is ongoing in select European countries. For more information, visit

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc. ("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for the APPY1 Test required for FDA submission, obtain FDA clearance or approval, maintain CE Marking, cost effectively manufacture and generate revenues from the APPY1 Test at a profitable price point, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis' recent filings with the SEC, including its Form 10-Q for the quarter ended June 30, 2013.

For Investors and Media:
Tiberend Strategic Advisors, Inc.

Joshua Drumm, PhD; (212) 375-2664

Claire Sojda; (212) 375-2686

SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Venaxis to Present at Canaccord Genuity 33rd Annual Growth Conference
2. Venaxis Appoints SomaLogic CMO and former Pfizer Executive Stephen A. Williams, M.D., Ph.D., to Board of Directors
3. Venaxis Advances Pivotal U.S. Study and Accelerates European Market Development for APPY1 Blood-based Appendicitis Test
4. Venaxis to Present at 25th Annual ROTH Conference
5. Venaxis Presentation Rescheduled for 2013 BIO CEO and Investor Conference
6. Venaxis to Present at 2013 BIO CEO and Investor Conference
7. AspenBio Pharma Changes Company Name to Venaxis, Inc.
8. Soligenix to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City
9. Isis Pharmaceuticals to Present at the 2013 Stifel Healthcare Conference
10. Lexicon To Present At The Morgan Stanley Global Healthcare Conference
11. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2013 On September 11, 2013
Post Your Comments:
(Date:11/26/2015)... 2015 --> ... combineert immunotherapie met Bremachlorin-photodynamische therapie voor de ... ) --> ... ) Uit een ... (LUMC) blijkt dat ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Therapeutic Drug Monitoring (TDM) Market: Supplier ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare ... participated in the 61st annual Employee Benefits Conference. The Employee Benefits Conference was ... November 8th through Wednesday, November 11th, 2015. The conference was held at the ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... has collaborated with Women’s Web – an online resource for Indian women ... mental and emotional well-being relationship, life balance, stress, professional development, and lifestyle. ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... more aggressive than those found on mammography, according to a study published online ... additional cancers not seen on mammography may necessitate a change in treatment. , ...
(Date:11/25/2015)... ... November 25, 2015 , ... The holiday season ... and pleasing the palates of attendees is of the utmost importance. Whether you ... seasonal get-together, give these recipes a try this holiday season. , Turkey Croquettes ...
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, one ... for its stellar workplace culture with the company’s Cincinnati office being named a ... Cincinnati office was named a finalist in Cincinnati Business Courier’s 13th annual Greater ...
Breaking Medicine News(10 mins):